Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions

Lipids

Volumn 48, Issue 10, 2013, Pages 957-965

  Kei, Anastazia ^a   Liberopoulos, Evangelos ^a   Tellis, Costantinos ^b   Elisaf, Moses ^a   Tselepis, Alexandros ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Fenofibrate; High density lipoprotein (HDL) subfraction profile; Lipoprotein associated phospholipase A2; Nicotinic acid; Rosuvastatin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; ROSUVASTATIN; SIMVASTATIN;

ADD ON THERAPY; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MIXED DYSLIPIDEMIA; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT FAILURE;

AGED; BLOOD CHEMICAL ANALYSIS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; FLUOROBENZENES; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NIACIN; PHOSPHOLIPASES A2; PYRIMIDINES; SULFONAMIDES;

EID: 84885187331     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-013-3826-y     Document Type: Article

References (38)

1. Link JJ, Rohatgi A, de Lemos JA (2007) HDL cholesterol: physiology, pathophysiology, and management. Curr Probl Cardiol 32:268-314
2. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ (2004) High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24:2181-2187
3. Guha M, Gao X, Jayaraman S, Gursky O (2008) Correlation of structural stability with functional remodeling of high-density lipoproteins: the importance of being disordered. Biochemistry 47:11393-11397
4. Kontush A, Chapman MJ (2006) Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3:144-153
5. Rallidis LS, Tellis CC, Lekakis J, Rizos I, Varounis C, Charalampopoulos A, Zolindaki M, Dagres N, Anastasiou-Nana M, Tselepis AD (2012) Lipoprotein-associated phospholipase a(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. J Am Coll Cardiol 60:2053-2060
6. Durrington P (2003) Dyslipidaemia. Lancet 362:717-731
7. Liberopoulos E, Vlasserou F, Mitrogianni Z, Papageorgantas I, Elisaf M (2012) Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece. Angiology 63:184-193
8. Kei A, Liberopoulos EN, Mikhailidis DP, Elisaf M (2013) Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia. Int J Clin Pract 67:412-419
9. Kei A, Liberopoulos E, Tellis K, Rizzo M, Elisaf M, Tselepis A. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidaemia: a randomized pilot trial. Eur J Clin Invest 2013
10. Third Report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421
11. Kostapanos MS, Milionis HJ, Filippatos TD, Christogiannis LG, Bairaktari ET, Tselepis AD, Elisaf MS (2009) Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther 14:5-13
12. Kakafika AI, Xenofontos S, Tsimihodimos V, Tambaki AP, Lourida ES, Kalaitzidis R, Cariolou MA, Elisaf M, Tselepis AD (2003) The PON1 M55L gene polymorphism is associated with reduced HDL-associated PAF-AH activity. J Lipid Res 44:1919-1926
13. Airan-Javia SL, Wolf RL, Wolfe ML, Tadesse M, Mohler E, Reilly MP (2009) Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. Am Heart J 157:687.e1-8
14. Morgan JM, Capuzzi DM, Baksh RI, Intenzo C, Carey CM, Reese D, Walker K (2003) Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 91:1432-1436
15. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S (2004) Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study. J Atheroscler Thromb 11:278-285
16. Ballantyne C, Gleim G, Liu N et al (2012) Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia. J Clin Lipidol 6:235-243
17. Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, Musliner TA (2008) Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 57:796-801
18. Miyazaki T, Shimada K, Miyauchi K, Kume A, Tanimoto K, Kiyanagi T, Sumiyoshi K, Hiki M, Mokuno H, Okazaki S, Sato H, Kurata T, Daida H (2010) Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting. Lipids Health Dis 9:122
19. Agouridis AP, Kostapanos MS, Tsimihodimos V, Kostara C, Mikhailidis DP, Bairaktari ET, Tselepis AD, Elisaf MS (2012) Effect of rosuvastatin monotherapy or in combination with fenofibrate or omega-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract 66:843-853
20. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR (2003) Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23:160-167
21. van der Hoorn JW, de Haan W, Berbee JF, Havekes LM, Jukema JW, Rensen PC, Princen HM (2008) Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE 3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 28:2016-2022
22. Rye KA, Clay MA, Barter PJ (1999) Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 145:227-238
23. Sasaki J, Yamamoto K, Ageta M (2002) Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study. Clin Ther 24:1614-1626
24. Lee MH, Hammad SM, Semler AJ, Luttrell LM, Lopes-Virella MF, Klein RL (2010) HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate. J Lipid Res 51:2619-2628
25. Gao X, Yuan S, Jayaraman S, Gursky O (2009) Differential stability of high-density lipoprotein subclasses: effects of particle size and protein composition. J Mol Biol 387:628-638
26. Lund-Katz S, Phillips MC (2010) High density lipoprotein structure-function and role in reverse cholesterol transport. Subcell Biochem 51:183-227
27. Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J (1991) HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 84:129-139
28. Lagos KG, Filippatos TD, Tsimihodimos V, Gazi IF, Rizos C, Tselepis AD, Mikhailidis DP, Elisaf MS (2009) Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids 44:9-16
29. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH (2003) Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23:712-719
30. Bergmeier C, Siekmeier R, Gross W (2004) Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem 50:2309-2315
31. Zheng C, Aikawa M (2012) High-density lipoproteins: from function to therapy. J Am Coll Cardiol 60:2380-2383
32. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP (2008) Multiple actions of high-density lipoprotein. Curr Opin Cardiol 23:370-378
33. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255-2267
34. Merck 2013 announces HPS2-THRIVE study of TREDAPTIVE™ (Extended-Release Niacin/Laropiprant) did not achieve primary endpoint. Available at: http://www.mercknewsroom.com/press-release/prescription-medicine- news/merck-announces-hps2-thrive-study-tredaptive-extended-relea. Last assessed 30 July 2013
35. Merck 2013 provides update on next steps for TREDAPTIVE™ (extended-release niacin/laropiprant) Available at: http://www.mercknewsroom. com/press-release/research-and-development-news/merck-provides-update-next- steps-tredaptive-extended-rel. Last assessed 30 July 2013
36. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362:1563-1574
37. Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, Tselepis AD (2003) Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 44:927-934
38. Tellis CC, Tselepis AD (2009) The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 1791:327-338